一种功能化锰基纳米疫苗复合水凝胶及其制备方法与应用
By constructing a tannic acid-modified functionalized manganese-based nanovaccine composite hydrogel, the problems of short circulating half-life, poor lymph node targeting, and insufficient regulation of the inflammatory microenvironment in the postoperative treatment of melanoma by tumor nanovaccines were solved. This enabled effective killing of tumor cells in lymph nodes and regulation of the postoperative immune environment, thereby inhibiting tumor recurrence and metastasis.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- SOUTHERN MEDICAL UNIVERSITY
- Filing Date
- 2024-07-04
- Publication Date
- 2026-07-17
AI Technical Summary
Existing tumor nanovaccines face challenges in the postoperative treatment of melanoma, including short circulating half-life, lack of lymph node targeting, inability to regulate the postoperative inflammatory microenvironment, and inability to kill tumor cells within lymph nodes.
A tannic acid-modified functionalized manganese-based nanovaccine composite hydrogel was constructed. The manganese-based nanovaccine was generated through a biomineralization reaction and crosslinked with a 4-aminophenylboronic acid-modified polysaccharide hydrogel to form a composite hydrogel with lymph node targeting and immune adjuvant activity, which can be used to regulate the postoperative immune environment.
It enhances the ability of nano-vaccines to accumulate in lymph nodes and kill tumor cells within the lymph nodes, regulates the postoperative inflammatory environment, and effectively inhibits tumor recurrence and metastasis.
Smart Images
Figure CN118846034B_ABST